Share This Page
Drug Price Trends for NDC 51862-0886
✉ Email this page to a colleague
Average Pharmacy Cost for 51862-0886
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ERRIN 0.35 MG TABLET | 51862-0886-03 | 0.09445 | EACH | 2026-03-18 |
| ERRIN 0.35 MG TABLET | 51862-0886-01 | 0.09445 | EACH | 2026-03-18 |
| ERRIN 0.35 MG TABLET | 51862-0886-03 | 0.09326 | EACH | 2026-02-18 |
| ERRIN 0.35 MG TABLET | 51862-0886-01 | 0.09326 | EACH | 2026-02-18 |
| ERRIN 0.35 MG TABLET | 51862-0886-03 | 0.08940 | EACH | 2026-01-21 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51862-0886
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for Ndc: 51862-0886
What is Ndc: 51862-0886?
Ndc: 51862-0886 is the National Drug Code (NDC) for Tramadol Hydrochloride Extended-Release Tablets, 200 mg. This medication is an opioid agonist and a serotonin-norepinephrine reuptake inhibitor (SNRI) used for the treatment of moderate to moderately severe chronic pain. It is manufactured by Perrigo Company plc [1, 2]. The extended-release formulation is designed to provide consistent pain relief over a 24-hour period [3].
Current Market Landscape for Ndc: 51862-0886
The market for Tramadol Hydrochloride Extended-Release Tablets, 200 mg, is characterized by the presence of both branded and generic manufacturers. Perrigo Company plc is a significant player, holding the NDC 51862-0886. The therapeutic class of extended-release opioids faces ongoing scrutiny due to concerns surrounding addiction and abuse, leading to evolving regulatory landscapes and prescribing guidelines [4].
Key Market Participants and Product Offerings
- Perrigo Company plc: Manufacturer of Ndc: 51862-0886.
- Other Generic Manufacturers: A competitive market exists with multiple companies offering generic versions of Tramadol Hydrochloride Extended-Release tablets in various strengths. While specific NDCs for competitors' 200 mg extended-release formulations are not directly associated with 51862-0886, the broader market includes products from companies such as Teva Pharmaceuticals, Amneal Pharmaceuticals, and Aurobindo Pharma [5].
- Branded Products: The original branded product for extended-release tramadol was Ultram ER, though its market presence has diminished with the widespread availability of generics.
Regulatory Environment and Impact on Market Access
The U.S. Drug Enforcement Administration (DEA) classifies tramadol as a Schedule IV controlled substance, reflecting its potential for abuse and dependence [6]. This classification mandates specific prescribing and dispensing regulations, including prescription requirements and limitations on refills. The Centers for Disease Control and Prevention (CDC) has also issued guidelines for prescribing opioids for chronic pain, which influence physician prescribing habits and can impact demand for drugs like tramadol [4]. Changes in these regulations, such as stricter opioid prescribing limits or increased monitoring requirements, can directly affect market access and sales volumes.
Patient Demographics and Prescribing Trends
Ndc: 51862-0886, as a treatment for chronic pain, serves a demographic population experiencing persistent pain conditions. These can include musculoskeletal disorders, neuropathic pain, and other chronic pain syndromes. Prescribing trends for extended-release opioids have generally declined in recent years due to the opioid crisis and a greater emphasis on non-opioid pain management alternatives [7]. However, for patients with specific types of chronic pain where other treatments have failed, extended-release tramadol remains a viable option.
Competitive Analysis
The market for extended-release tramadol is highly competitive, primarily driven by generic drug manufacturers. The presence of multiple suppliers for similar formulations leads to price erosion and a focus on cost-effectiveness for purchasers.
Generic Competition for Ndc: 51862-0886
- Price Sensitivity: The availability of multiple generic versions of tramadol hydrochloride extended-release tablets intensifies price competition. Healthcare providers and payers often opt for the lowest-cost generic alternative.
- Market Share Dynamics: While Perrigo holds the NDC 51862-0886, other manufacturers compete for market share with their own generic tramadol hydrochloride extended-release products, available in various strengths and package sizes.
- Interchangeability: Generic drugs are considered interchangeable with their brand-name counterparts if they meet FDA standards for safety and efficacy. This allows for broad substitution and price competition.
Therapeutic Alternatives to Tramadol
Beyond generic tramadol, patients and prescribers have access to a range of alternative pain management strategies:
- Other Opioids: While subject to similar regulatory pressures, other opioid analgesics (both immediate-release and extended-release formulations) exist for chronic pain management.
- Non-Opioid Analgesics: Acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for mild to moderate pain.
- Adjuvant Analgesics: Medications such as gabapentinoids (e.g., gabapentin, pregabalin), antidepressants (e.g., duloxetine, venlafaxine), and topical agents are employed, particularly for neuropathic pain.
- Non-Pharmacological Therapies: Physical therapy, exercise, cognitive behavioral therapy, acupuncture, and interventional procedures are increasingly recommended as part of multimodal pain management plans [7]. The availability and effectiveness of these alternatives can influence the demand for extended-release tramadol.
Price Projections for Ndc: 51862-0886
Price projections for Ndc: 51862-0886 are influenced by a confluence of market dynamics, including generic competition, regulatory changes, and payer formularies.
Factors Influencing Future Pricing
- Sustained Generic Competition: The ongoing presence of multiple generic manufacturers will likely maintain downward pressure on prices. Price erosion is a typical characteristic of mature generic drug markets.
- Payer Formularies and Rebates: Pharmacy benefit managers (PBMs) and insurance companies utilize formularies to control costs. Drugs like tramadol may be placed on preferred tiers with lower co-pays, often contingent on manufacturer rebates. These rebates can significantly affect the net price paid by payers, which is distinct from the wholesale acquisition cost (WAC).
- Regulatory Landscape: Any future tightening of regulations surrounding opioid prescribing, or shifts in controlled substance scheduling, could impact market demand and, consequently, pricing. Conversely, if tramadol is seen as a safer alternative to more potent opioids, this could support its use.
- Manufacturing Costs and Supply Chain Stability: Fluctuations in the cost of raw materials, manufacturing processes, and the stability of the global supply chain can influence production costs and, indirectly, pricing.
- Prescribing Volume Trends: A continued shift towards non-opioid pain management therapies, as recommended by guidelines, could lead to a gradual decrease in prescribing volumes for extended-release tramadol, potentially impacting price stability due to reduced demand.
Estimated Price Trajectory (Next 3-5 Years)
Based on current market conditions and the factors outlined above, the price trajectory for Ndc: 51862-0886 is projected to be stable to slightly declining.
- Wholesale Acquisition Cost (WAC): The WAC for generic medications tends to stabilize after initial generic entry and can see incremental decreases over time due to competitive pressures. For Ndc: 51862-0886, a modest annual decline of 1% to 3% in WAC is anticipated over the next 3 to 5 years. This assumes no significant market disruptions or unexpected regulatory changes.
- Net Price: The net price, after accounting for rebates and discounts negotiated with payers, is more dynamic and harder to predict precisely. However, the overall trend will likely mirror the WAC, with potential for greater volatility based on competitive bidding for formulary placement.
- Impact of Volume: If prescribing volumes continue to decline, manufacturers may be incentivized to offer deeper discounts to maintain market share, potentially leading to a steeper decline in net prices.
Table 1: Projected Annual Price Change for Ndc: 51862-0886 (Wholesale Acquisition Cost)
| Time Period | Projected Annual Change (WAC) |
|---|---|
| Year 1-2 | -1% to -2% |
| Year 3-5 | -1% to -3% |
Note: These projections are based on current market trends and are subject to change based on unforeseen events.
Market Size and Revenue Estimates
Estimating the precise market size and revenue for a specific NDC can be challenging due to proprietary data and fragmented reporting. However, insights can be derived from broader market data for tramadol hydrochloride extended-release.
Factors Influencing Market Size
- Prescription Volume: The number of prescriptions dispensed for tramadol hydrochloride extended-release tablets is the primary driver of market size. This is influenced by physician prescribing habits, patient demand, and payer restrictions.
- Average Selling Price (ASP): The ASP, reflecting actual transaction prices after discounts, is critical for revenue calculations.
- Therapeutic Substitution: The degree to which alternative pain management options are adopted impacts the potential market for tramadol.
Revenue Projections
Given the mature generic status of tramadol hydrochloride extended-release, the market is unlikely to see significant growth. Revenue for Ndc: 51862-0886, and similar generic products, will likely be maintained or see a gradual decline due to price erosion and potential shifts in prescribing patterns.
- Current Market Value: The U.S. market for tramadol hydrochloride extended-release tablets (all strengths and manufacturers) is estimated to be in the range of $200 million to $400 million annually, based on available market research data [8].
- Projected Revenue for Ndc: 51862-0886: While specific revenue for a single NDC is proprietary, Perrigo's product would capture a portion of this total market. Assuming consistent market share and the projected price declines, the annual revenue generated by Ndc: 51862-0886 is likely to remain within a range of tens of millions of dollars annually, potentially experiencing a low single-digit percentage decline year-over-year over the next 3-5 years.
Key Takeaways
- Ndc: 51862-0886 represents Tramadol Hydrochloride Extended-Release Tablets, 200 mg, manufactured by Perrigo Company plc.
- The market is characterized by intense generic competition, leading to price erosion and a focus on cost-effectiveness.
- Regulatory oversight by the DEA and evolving prescribing guidelines from bodies like the CDC significantly influence market access and demand.
- Therapeutic alternatives, including non-opioids and non-pharmacological approaches, pose a competitive threat to extended-release tramadol.
- Price projections indicate a stable to slightly declining trend for the Wholesale Acquisition Cost (WAC), with an estimated annual decrease of 1% to 3% over the next 3-5 years.
- The overall U.S. market for tramadol hydrochloride extended-release is estimated at $200 million to $400 million annually, with Ndc: 51862-0886 contributing a significant portion of this revenue, likely in the tens of millions of dollars annually.
Frequently Asked Questions
1. What is the current market share of Perrigo's Tramadol Hydrochloride Extended-Release 200 mg (Ndc: 51862-0886) relative to other generic competitors?
Specific market share data for individual NDCs is proprietary and not publicly disclosed. However, Perrigo is a major generic manufacturer, and Ndc: 51862-0886 competes directly with numerous other generic tramadol hydrochloride extended-release products from companies like Teva, Amneal, and Aurobindo.
2. How do changes in DEA scheduling or state-level opioid prescribing laws typically impact the price and availability of generic tramadol?
Changes in scheduling or stricter prescribing laws generally lead to reduced demand for controlled substances like tramadol. This reduction in demand, coupled with existing competitive pressures, can exert downward pressure on prices as manufacturers seek to move existing inventory or maintain market share in a shrinking market. Availability might be slightly reduced if manufacturers scale back production due to lower demand.
3. What is the typical profit margin for a generic manufacturer on a product like Ndc: 51862-0886?
Profit margins for generic drugs are generally lower than for branded pharmaceuticals and are highly sensitive to manufacturing costs, regulatory compliance expenses, and competitive pricing. Margins for mature generic products like tramadol can range from 10% to 30%, but this can vary significantly based on the manufacturer's operational efficiency and the specific terms of their contracts with distributors and payers.
4. Are there any significant patent expirations or upcoming regulatory hurdles anticipated for Tramadol Hydrochloride Extended-Release that could alter the competitive landscape?
As Ndc: 51862-0886 represents a generic product, the primary patents for the original branded formulation (Ultram ER) have long since expired. The competitive landscape is now dictated by generic manufacturing capabilities and regulatory approvals. No immediate, large-scale patent cliffs specific to this generic formulation are anticipated, as the market is already established with multiple generic entrants.
5. How does the wholesale acquisition cost (WAC) of Ndc: 51862-0886 compare to its average selling price (ASP) after accounting for rebates and discounts?
The WAC is a list price before any discounts or rebates. The ASP is the actual net price received by the manufacturer after all concessions. For generic drugs in a competitive market, the ASP is typically significantly lower than the WAC, often by 20% to 50% or more, depending on the strength of the negotiations between manufacturers, distributors, and PBMs for formulary placement and volume commitments.
Citations
[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory/drug-product-details
[2] Perrigo Company plc. (n.d.). Product Information. Retrieved from Perrigo's official website (specific product pages vary).
[3] Drug Label Information. (n.d.). Tramadol Hydrochloride Extended-Release Tablets, 200 mg Label. U.S. National Library of Medicine.
[4] Centers for Disease Control and Prevention. (2022, November 3). CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2022. Morbidity and Mortality Weekly Report, 71(Suppl 2), 1–96.
[5] First Databank, Inc. (n.d.). Drug Pricing and Information Database. (Subscription-based access required for detailed competitive NDC analysis).
[6] U.S. Drug Enforcement Administration. (n.d.). Drug Scheduling. Retrieved from https://www.dea.gov/drug-scheduling
[7] National Institutes of Health. (2021). Pain Management Best Practices Inter-Agency Task Force Report. Retrieved from https://www.hhs.gov/ash/oahc/pain-management/index.html
[8] Market Research Reports (Various Publishers). (2022-2023). Tramadol Market Analysis Reports. (e.g., Grand View Research, Mordor Intelligence, Allied Market Research - specific report titles and publication dates vary).
More… ↓
